Epilepsy Treatment in Germany

Epilepsy is one of the most common serious neurological disorders, affecting approximately 50 million people worldwide. Approximately one-third of patients with epilepsy do not achieve adequate seizure control with antiseizure medications, constituting drug-resistant epilepsy — a condition that carries significant risks of injury, cognitive impairment, and reduced quality of life. German university hospitals operate dedicated epilepsy centres that provide the full spectrum of diagnostic evaluation and treatment, from optimisation of antiseizure medication regimens to comprehensive presurgical evaluation and surgical intervention. These centres are accredited by the German Society for Epileptology and operate within European epilepsy networks, ensuring that patients receive care aligned with current international standards. For international patients with drug-resistant epilepsy or diagnostic uncertainty, German epilepsy specialists offer structured evaluation that addresses the accuracy of the epilepsy syndrome diagnosis, the completeness of the presurgical workup, and the available treatment options including surgery and neuromodulation.

About the Condition

Epilepsy is defined by the occurrence of two or more unprovoked seizures separated by more than 24 hours, or one unprovoked seizure with a high probability of recurrence. Seizures arise from abnormal, excessive, or synchronous neuronal activity in the brain and are classified according to their onset as focal (arising from a network limited to one hemisphere), generalised (arising from networks distributed across both hemispheres), or of unknown onset. Epilepsy syndromes are defined by the combination of seizure types, EEG characteristics, neuroimaging findings, age of onset, and genetic or structural aetiology. Accurate syndrome classification is essential for treatment selection, as different syndromes respond differently to specific antiseizure medications and have distinct surgical candidacy profiles. Drug-resistant epilepsy is defined by failure of adequate trials of two tolerated and appropriately chosen antiseizure medication schedules, whether as monotherapies or in combination, to achieve sustained seizure freedom.

Common Symptoms

• Focal aware seizures — brief episodes of abnormal sensory, motor, autonomic, or psychic symptoms without loss of awareness
• Focal impaired awareness seizures — episodes with altered consciousness, often accompanied by automatisms such as lip smacking or hand fumbling
• Focal to bilateral tonic-clonic seizures — spreading from a focal onset to involve both hemispheres with generalised convulsive activity
• Absence seizures — brief episodes of unresponsiveness with staring, typically lasting 5-30 seconds, without post-ictal confusion
• Myoclonic jerks — sudden, brief, involuntary muscle contractions, often occurring in the morning
• Tonic-clonic seizures — loss of consciousness with tonic stiffening followed by clonic jerking of the limbs
• Atonic seizures — sudden loss of muscle tone causing falls, associated with significant injury risk
• Post-ictal confusion, headache, or focal neurological deficit following seizures

Causes and Risk Factors

Epilepsy arises from a broad range of structural, genetic, infectious, metabolic, immune, and unknown aetiologies. Structural causes include hippocampal sclerosis (the most common cause of drug-resistant focal epilepsy), cortical dysplasia, brain tumours, vascular malformations, post-traumatic scarring, and stroke. Genetic epilepsies include channelopathies such as SCN1A mutations causing Dravet syndrome, KCNQ2 mutations, and a growing number of genes identified through next-generation sequencing panels. Autoimmune epilepsies, including those associated with NMDA receptor, LGI1, CASPR2, and GABA-B receptor antibodies, represent an important and treatable cause of new-onset epilepsy, particularly in adults. Infectious causes include neurocysticercosis, herpes simplex encephalitis, and other CNS infections. Metabolic causes include pyridoxine-dependent epilepsy, glucose transporter deficiency, and mitochondrial disorders. In a substantial proportion of patients, no specific aetiology is identified despite comprehensive investigation.

Diagnostic Process in Germany

Presurgical evaluation at German epilepsy centres follows a structured protocol designed to identify the epileptogenic zone — the cortical area whose resection or disconnection is necessary and sufficient to render the patient seizure-free. Long-term video-EEG monitoring with scalp electrodes records seizure semiology and ictal EEG patterns, allowing localisation of seizure onset and correlation with clinical features. High-resolution MRI at 3 Tesla using epilepsy-specific protocols (thin-slice T1, FLAIR, T2, and inversion recovery sequences) identifies structural lesions including subtle cortical dysplasia. FDG-PET imaging demonstrates interictal hypometabolism in the epileptogenic zone. Ictal SPECT, when performed during a seizure, shows hyperperfusion at the seizure onset zone. Magnetoencephalography (MEG) provides complementary information on interictal spike localisation. Where non-invasive investigations are inconclusive, intracranial EEG recording using stereoelectroencephalography (SEEG) or subdural grid electrodes is performed to precisely delineate the epileptogenic zone and its relationship to eloquent cortex.

Treatment Options in Germany

Treatment of epilepsy at German university hospitals begins with optimisation of antiseizure medication therapy, guided by epilepsy syndrome classification, seizure type, and individual patient factors including age, sex, comorbidities, and teratogenic risk in women of childbearing potential. When drug-resistant epilepsy is established, presurgical evaluation is initiated to determine whether surgical resection or disconnection is feasible. Resective surgery — including temporal lobectomy, lesionectomy, and extratemporal resections — offers the possibility of seizure freedom in appropriately selected patients, with temporal lobe surgery achieving seizure freedom in 60-70% of cases at experienced centres. Laser interstitial thermal therapy (LITT) provides a minimally invasive alternative for selected lesional epilepsies. For patients who are not surgical candidates, neuromodulation options include vagus nerve stimulation (VNS), deep brain stimulation of the anterior thalamic nucleus (DBS-ANT), and responsive neurostimulation (RNS). The ketogenic diet and its variants are offered as adjunctive therapy, particularly for children with drug-resistant epilepsy.

• Antiseizure medication optimisation with syndrome-specific drug selection and therapeutic drug monitoring
• Temporal lobectomy and selective amygdalohippocampectomy for mesial temporal lobe epilepsy
• Lesionectomy and cortical resection for structural epilepsies (cortical dysplasia, tumours, vascular malformations)
• Laser interstitial thermal therapy (LITT) for minimally invasive treatment of selected lesional epilepsies
• Stereoelectroencephalography (SEEG) for invasive presurgical evaluation of complex cases
• Vagus nerve stimulation (VNS) for drug-resistant epilepsy not amenable to resective surgery
• Deep brain stimulation of the anterior thalamic nucleus (DBS-ANT) for drug-resistant focal epilepsy
• Ketogenic diet therapy as adjunctive treatment, particularly for children with drug-resistant epilepsy

Why Treatment in Germany

German epilepsy centres accredited by the German Society for Epileptology provide the full spectrum of presurgical evaluation technology within a single institutional framework, including long-term video-EEG monitoring, high-resolution MRI with epilepsy-specific protocols, FDG-PET, ictal SPECT, MEG, and intracranial EEG recording. The multidisciplinary epilepsy conference — bringing together epileptologists, neurosurgeons, neuroradiologists, neuropsychologists, and nuclear medicine specialists — reviews each presurgical case to reach a consensus on the epileptogenic zone and the optimal surgical strategy. German epilepsy surgery centres report outcomes consistent with international benchmarks, and the availability of minimally invasive techniques including LITT and SEEG has expanded the range of patients who can benefit from surgical evaluation. For patients with drug-resistant epilepsy who have not been evaluated at a dedicated epilepsy centre, German specialists provide an independent assessment of surgical candidacy and available treatment options.

Specialist Evaluation

An epilepsy specialist evaluation at a German university hospital begins with a detailed review of the seizure history, prior EEG recordings, neuroimaging, and antiseizure medication trials. The epileptologist assesses the accuracy of the epilepsy syndrome diagnosis, determines whether drug-resistant epilepsy criteria are met, and evaluates whether the presurgical workup is complete and appropriately interpreted. For patients who have undergone presurgical evaluation elsewhere, the evaluation addresses whether the proposed surgical strategy is supported by the available data and whether additional investigations are indicated. The evaluation report provides a structured clinical opinion with specific recommendations for further investigation, treatment optimisation, and surgical candidacy.

Patient Pathway

1. 1

   Submit clinical history, all available EEG recordings (including video-EEG if available), MRI studies, and documentation of prior antiseizure medication trials

2. 2

   Clinical coordinator reviews documentation and routes the case to the epilepsy subspecialty team

3. 3

   Epileptologist reviews all available data, assesses syndrome classification and drug-resistance status, and identifies any additional investigations required

4. 4

   Structured evaluation report prepared with diagnostic opinion, drug-resistance assessment, and surgical candidacy evaluation

5. 5

   Case directed to the relevant university hospital epilepsy centre for formal presurgical evaluation and treatment planning

6. 6

   Ongoing coordination of presurgical workup, surgical planning, and post-operative seizure management

Related Conditions and Services